AR093476A1 - Composiciones y metodos para el tratamiento de la displasia ectodermica - Google Patents
Composiciones y metodos para el tratamiento de la displasia ectodermicaInfo
- Publication number
- AR093476A1 AR093476A1 ARP130104180A ARP130104180A AR093476A1 AR 093476 A1 AR093476 A1 AR 093476A1 AR P130104180 A ARP130104180 A AR P130104180A AR P130104180 A ARP130104180 A AR P130104180A AR 093476 A1 AR093476 A1 AR 093476A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- compositions
- methods
- ectodermal dysplasia
- protein monomer
- Prior art date
Links
- 208000002169 ectodermal dysplasia Diseases 0.000 title abstract 4
- 208000031068 ectodermal dysplasia syndrome Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 5
- 239000000178 monomer Substances 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 108010060271 Fc-EDA Proteins 0.000 abstract 1
- 208000026350 Inborn Genetic disease Diseases 0.000 abstract 1
- 229920001213 Polysorbate 20 Polymers 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000003599 detergent Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 208000016361 genetic disease Diseases 0.000 abstract 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 abstract 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 abstract 1
- 229940068977 polysorbate 20 Drugs 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 239000001488 sodium phosphate Substances 0.000 abstract 1
- 229910000162 sodium phosphate Inorganic materials 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Composiciones farmacéuticas y métodos para el tratamiento de displasias ectodérmicas mediante la administración de agonistas de EDA (displasia ectodérmica anhidrótica), en particular EDI200. El uso de las composiciones y métodos descritos permite la dosificación terapéutica y regímenes de administración en pacientes humanos para corregir o alterar los fenotipos anormales asociadas con trastornos genéticos, en particular, XLHED (displasia ectodérmica hipodrótica ligada al X). Reivindicación 1: Una composición farmacéutica caracterizada porque comprende al menos un monómero proteico, en donde dicho monómero proteico comprende SEQ ID Nº 1 y en donde dicho al menos un monómero proteico está glicosilado en las posiciones Asn76 y Asn302, y un excipiente farmacéuticamente aceptable. Reivindicación 6: La composición farmacéutica de la reivindicación 1, caracterizada porque el excipiente farmacéuticamente aceptable es un diluyente que comprende fosfato de sodio y cloruro de sodio. Reivindicación 7: La composición farmacéutica de la reivindicación 6, caracterizada porque además comprende uno o más tensioactivos y/o detergentes. Reivindicación 8: La composición farmacéutica de la reivindicación 7, caracterizada porque además comprende polisorbato 20.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261726252P | 2012-11-14 | 2012-11-14 | |
| US201361825227P | 2013-05-20 | 2013-05-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR093476A1 true AR093476A1 (es) | 2015-06-10 |
Family
ID=50731641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130104180A AR093476A1 (es) | 2012-11-14 | 2013-11-13 | Composiciones y metodos para el tratamiento de la displasia ectodermica |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20160272694A1 (es) |
| EP (1) | EP2920318A4 (es) |
| JP (1) | JP2015536344A (es) |
| KR (1) | KR20150099720A (es) |
| AR (1) | AR093476A1 (es) |
| AU (1) | AU2013344973B2 (es) |
| BR (1) | BR112015011099A2 (es) |
| CA (1) | CA2891386A1 (es) |
| IL (1) | IL238602A0 (es) |
| MX (1) | MX2015005993A (es) |
| RU (1) | RU2015117995A (es) |
| SG (1) | SG11201503777YA (es) |
| TW (1) | TW201438730A (es) |
| WO (1) | WO2014078353A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3060245B1 (en) * | 2013-10-22 | 2020-02-26 | EspoirXLHED Sàrl | Intra-amniotic administration of proteins for the treatment of ectodermal dysplasias |
| JP2020154178A (ja) * | 2019-03-20 | 2020-09-24 | ヤフー株式会社 | 情報処理装置、情報処理方法および情報処理プログラム |
| JP2020154179A (ja) * | 2019-03-20 | 2020-09-24 | ヤフー株式会社 | 情報処理装置、情報処理方法および情報処理プログラム |
| JP2020154180A (ja) * | 2019-03-20 | 2020-09-24 | ヤフー株式会社 | 情報処理装置、情報処理方法および情報処理プログラム |
| CN114145452B (zh) * | 2021-12-10 | 2022-11-01 | 青岛圣桐营养食品有限公司 | 特殊医学用途全营养配方食品 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6506569B1 (en) * | 1997-05-30 | 2003-01-14 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor TR10 |
| WO2003068977A2 (de) * | 2002-02-10 | 2003-08-21 | Apoxis Sa | Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden |
| US9175085B2 (en) * | 2011-05-13 | 2015-11-03 | Edimer Pharmaceuticals, Inc. | Treatment of X-linked hypohidrotic ectodermal dysplasia with ectodysplasin A agonist |
-
2013
- 2013-11-13 SG SG11201503777YA patent/SG11201503777YA/en unknown
- 2013-11-13 MX MX2015005993A patent/MX2015005993A/es unknown
- 2013-11-13 CA CA2891386A patent/CA2891386A1/en not_active Abandoned
- 2013-11-13 AR ARP130104180A patent/AR093476A1/es unknown
- 2013-11-13 EP EP13854763.3A patent/EP2920318A4/en not_active Withdrawn
- 2013-11-13 TW TW102141295A patent/TW201438730A/zh unknown
- 2013-11-13 KR KR1020157012781A patent/KR20150099720A/ko not_active Withdrawn
- 2013-11-13 BR BR112015011099A patent/BR112015011099A2/pt not_active IP Right Cessation
- 2013-11-13 WO PCT/US2013/069799 patent/WO2014078353A1/en not_active Ceased
- 2013-11-13 US US14/442,324 patent/US20160272694A1/en not_active Abandoned
- 2013-11-13 AU AU2013344973A patent/AU2013344973B2/en not_active Expired - Fee Related
- 2013-11-13 RU RU2015117995A patent/RU2015117995A/ru not_active Application Discontinuation
- 2013-11-13 JP JP2015542738A patent/JP2015536344A/ja active Pending
-
2015
- 2015-05-03 IL IL238602A patent/IL238602A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013344973A1 (en) | 2015-05-14 |
| US20160272694A1 (en) | 2016-09-22 |
| RU2015117995A (ru) | 2017-01-10 |
| EP2920318A4 (en) | 2016-04-13 |
| EP2920318A1 (en) | 2015-09-23 |
| SG11201503777YA (en) | 2015-06-29 |
| KR20150099720A (ko) | 2015-09-01 |
| IL238602A0 (en) | 2015-06-30 |
| WO2014078353A1 (en) | 2014-05-22 |
| MX2015005993A (es) | 2015-12-09 |
| BR112015011099A2 (pt) | 2017-08-22 |
| TW201438730A (zh) | 2014-10-16 |
| JP2015536344A (ja) | 2015-12-21 |
| AU2013344973B2 (en) | 2016-10-06 |
| CA2891386A1 (en) | 2014-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010140A (es) | Nuevos metodos. | |
| JOP20200222A1 (ar) | أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون | |
| PE20241305A1 (es) | Analogos de amilina | |
| MX2019010354A (es) | Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo. | |
| MX2017010287A (es) | Composiciones farmaceuticas que comprenden n-(3,5-dimetoxifenil)-n '-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il)quinoxalin-6-il]eta no-1,2-diamina. | |
| CL2016001411A1 (es) | Unidad de dosificación farmacéutica solida de desintegración oral que comprende un componente de estetrol; metodo de preparación; uso para la anticoncepción femenina y en terápia de sustitución hormonal femenina. | |
| MX2020010999A (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos. | |
| AR086409A1 (es) | Formulaciones de gel bioadhesivo de testosterona intranasal y uso del mismo para tratar hipogonadismo masculino | |
| MX2019003468A (es) | Derivados de tieno [3,2-d]pirimidina que tienen actividad inhibidora de las cinasas de proteina. | |
| BR112014028633A8 (pt) | tratamento de amd usando sflt-1 de aav | |
| MD4430B1 (ro) | Compoziţii şi metode de tratament al hepatitei virale C | |
| UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
| MX2016010179A (es) | Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer. | |
| BR112014007902A2 (pt) | composições farmacêuticas compreendendo 40-o-(2-hidróxi)etil-rapamicina | |
| PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
| AR093476A1 (es) | Composiciones y metodos para el tratamiento de la displasia ectodermica | |
| JO3122B1 (ar) | مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية | |
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
| AR086800A1 (es) | Composicion farmaceutica oftalmologica topica que contiene regorafenib | |
| AR076505A1 (es) | Uso de alopurinol para el tratamiento de la reaccion cutanea en manos -pies | |
| BR112015012497A8 (pt) | combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial | |
| MX2020008360A (es) | Forma cristalina de bictegravir sodico. | |
| MX391191B (es) | Composiciones de liberación extendida de onapristona y métodos. | |
| WO2015183984A3 (en) | Therapeutic compositions including tocopherol and uses thereof | |
| AR037496A1 (es) | Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |